/
SGMT
$7.79+$0.73 (+10.34%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$436.0M
62M shares
52-week range
$4.50 – $11.41
48% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.55%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-8.16
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $2.0M | $0 | $0 |
| Cost of revenue | $88.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$88.0K | $0 | $0 | $0 | $2.0M | $0 | $0 |
| Gross margin | — | — | — | — | 100.0% | — | — |
| R&D | $8.4M | $8.2M | $19.3M | $24.9M | $19.8M | $38.4M | $39.1M |
| Operating income | −$14.2M | −$11.4M | −$23.7M | −$31.1M | −$30.7M | −$54.5M | −$56.9M |
| EBITDA | −$14.1M | −$11.4M | −$24.4M | −$30.4M | −$27.9M | −$45.6M | −$51.0M |
| Net income | −$14.3M | −$11.4M | −$24.4M | −$30.5M | −$27.9M | −$45.6M | −$51.0M |
| Net margin | — | — | — | — | -1393.8% | — | — |
| EPS (diluted) | -0.64 | -0.51 | -1.10 | -1.38 | -1.53 | -1.45 | -1.58 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $111111 | $-1.20 | $-1.54–$-0.93 | 7 |
| 2027 | $8M | $-1.25 | $-1.66–$-0.77 | 7 |
| 2028 | $24M | $-1.63 | $-3.03–$-0.90 | 8 |
| 2029 | $91M | $-0.98 | $-0.98–$-0.98 | 6 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.05
Price
$7.79
Implied downside
-87%
Peer comparison
Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
www.sagimet.com- Employees
- 16
- IPO / List date
- Jul 14, 2023
- HQ
- SAN MATEO, CA
Held by traders on TradeandTell
No one on the platform currently holds SGMT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 625,469 | $3.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded SGMT yet.
